Tocilizumab-aazg · Regulatory label update

FDA supplemental approval: Tyenne (Labeling)

U.S. Food and Drug Administration · May 21, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved a supplemental labeling change for tocilizumab-aazg (Tyenne), a tocilizumab biosimilar manufactured by Fresenius Kabi, on 21 May 2026. This is a regulatory action affecting product labeling only; the record does not contain or summarize clinical trial results, efficacy data, or safety findings.

What was studied

Regulatory label update.

Key findings

FDA approved supplemental labeling for TYENNE (tocilizumab-aazg) in three intravenous formulations: 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL

Safety

This record reports only a labeling supplement, not clinical trial data, efficacy, comparative effectiveness, or new safety findings.

Who this may help

This labeling approval does not itself convey clinical efficacy or safety evidence. Clinicians should consult the updated product label and the underlying BLA approval for clinical information regarding tocilizumab-aazg use.

Plain-language summary

FDA supplemental approval of labeling for tocilizumab-aazg (Tyenne); a regulatory action affecting product information but not reporting new clinical trial data.

Reported figures

Quoted from the source exactly as published.

Approval date2026-05-21

Product formulation 180 mg/4 mL

Product formulation 2200 mg/10 mL

Product formulation 3400 mg/20 mL

Clinical bottom line

Caveats

This record reports only a labeling supplement, not clinical trial data, efficacy, comparative effectiveness, or new safety findings.
Specific content of the labeling change is not detailed in this regulatory record.
No clinical populations, sample sizes, endpoints, or outcomes are reported.
Original BLA approval data and clinical evidence are not included in this document.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory action record; no clinical study design present.

Directness

insufficient

Labeling action does not report clinical outcomes or comparative efficacy data.

Consistency

insufficient

Single regulatory action; no comparison to prior studies reported.

Risk of bias

insufficient

Regulatory submission; bias assessment not applicable to labeling approval.

Sample adequacy

insufficient

No clinical trial population reported in this regulatory record.

Source abstract

Drugs@FDA record for application BLA761275. This is a regulatory action record, not a clinical study. Brand name: TYENNE. Active ingredient: TOCILIZUMAB-AAZG. Sponsor: FRESENIUS KABI USA. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-05-21. Products: TYENNE, INJECTABLE, INTRAVENOUS, TOCILIZUMAB-AAZG 400MG/20ML; TYENNE, INJECTABLE, INTRAVENOUS, TOCILIZUMAB-AAZG 80MG/4ML; TYENNE, INJECTABLE, INTRAVENOUS, TOCILIZUMAB-AAZG 200MG/10ML.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Fresenius Kabi UTocilizumab-aazg